What is he best known for?
The fields of study he is best known for:
- Enzyme
- Biochemistry
- Organic chemistry
His main research concerns Biochemistry, Chromatography, Drug carrier, Protein aggregation and Microsphere.
His work deals with themes such as Antibody and Isotonic, which intersect with Biochemistry.
Jeffrey L. Cleland has researched Chromatography in several fields, including Trehalose, Polyethylene glycol and Diluent.
Drug carrier is a primary field of his research addressed under Pharmacology.
His Protein aggregation research includes themes of Crystallography, Biophysics, Denaturation and Infrared spectroscopy.
His Microsphere research incorporates elements of Human growth hormone and Active ingredient.
His most cited work include:
- Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover (1087 citations)
- The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. (618 citations)
- A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner (334 citations)
What are the main themes of his work throughout his whole career to date?
Jeffrey L. Cleland spends much of his time researching Biochemistry, Pharmacology, Chromatography, In vivo and PLGA.
His studies deal with areas such as Biophysics and Microsphere as well as Biochemistry.
His Chromatography study integrates concerns from other disciplines, such as Sucrose, Polysorbate 20, Antibody and Isotonic.
Within one scientific family, Jeffrey L. Cleland focuses on topics pertaining to Endocrinology under In vivo, and may sometimes address concerns connected to Growth factor.
His studies in PLGA integrate themes in fields like Adjuvant and Drug carrier, Drug delivery.
The various areas that Jeffrey L. Cleland examines in his Drug carrier study include Liberation and Dosage form.
He most often published in these fields:
- Biochemistry (25.69%)
- Pharmacology (18.75%)
- Chromatography (15.28%)
What were the highlights of his more recent work (between 2011-2021)?
- Sunitinib (4.86%)
- Pharmacology (18.75%)
- Biomedical engineering (7.64%)
In recent papers he was focusing on the following fields of study:
Sunitinib, Pharmacology, Biomedical engineering, Dendrimer and In vivo are his primary areas of study.
His study on Sunitinib also encompasses disciplines like
- Macular degeneration which is related to area like Polymeric matrix, Solvent system, Corneal neovascularization, Controlled release and Cytotoxicity,
- Choroidal neovascularization that intertwine with fields like Cancer research, Diabetic retinopathy, Tyrosine-kinase inhibitor and Leukostasis.
The study incorporates disciplines such as VEGF receptors and Platelet-derived growth factor receptor in addition to Pharmacology.
His Biomedical engineering research focuses on Microparticle and how it relates to Extended release.
His In vivo research incorporates themes from Hormone, Receptor, Potency and Pharmacodynamics.
Biochemistry is frequently linked to Vascular endothelial growth factor in his study.
Between 2011 and 2021, his most popular works were:
- A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life (59 citations)
- Scalable synthesis and validation of PAMAM dendrimer-N-acetyl cysteine conjugate for potential translation. (19 citations)
- Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles (14 citations)
In his most recent research, the most cited papers focused on:
- Enzyme
- Biochemistry
- Organic chemistry
Jeffrey L. Cleland mainly focuses on Sunitinib, Choroid, Ophthalmology, In vivo and Macular degeneration.
He interconnects Medical therapy, Pharmacokinetics, Biomedical engineering and Microparticle in the investigation of issues within In vivo.
He has included themes like Endocrinology and Growth hormone deficiency in his Pharmacokinetics study.
His Macular degeneration research is multidisciplinary, relying on both Polymeric matrix, Solvent system, Corneal neovascularization, Controlled release and Cytotoxicity.
He regularly ties together related areas like Pharmacology in his Cytotoxicity studies.
His research combines Potency and Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
